New developments in therapy for colorectal cancer

Current Oncology Reports

Volumn 5, Issue 3, 2003, Pages 183-191

  Gill, Sharlene ^a   Goldberg, Richard M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; ALCOHOL; BEVACIZUMAB; BILIRUBIN; CAPECITABINE; CETUXIMAB; DIHYDROPYRIMIDINE DEHYDROGENASE; EDRECOLOMAB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; SMAD2 PROTEIN; SMAD4 PROTEIN; TEGAFUR; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR SUPPRESSOR PROTEIN; UFT; URACIL;

BLEEDING; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; CARCINOGENESIS; CATHETER ABLATION; CHROMOSOME 18Q; CLINICAL TRIAL; COLON RESECTION; COLORECTAL CANCER; COLORECTAL SURGERY; CRYOTHERAPY; DIARRHEA; DRUG RESPONSE; DRUG SAFETY; ELDERLY CARE; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HETEROZYGOSITY LOSS; HUMAN; HYPERBILIRUBINEMIA; LAPAROSCOPIC SURGERY; LENGTH OF STAY; LIVER METASTASIS; LIVER RESECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MONOTHERAPY; NAUSEA AND VOMITING; PATIENT CARE; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PREOPERATIVE RADIOTHERAPY; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; REVIEW; STOMATITIS; SURGICAL TECHNIQUE; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT OUTCOME; COLORECTAL TUMOR; DISEASE MANAGEMENT; RESEARCH; STANDARD; UNITED STATES;

CLINICAL TRIALS; COLORECTAL NEOPLASMS; DISEASE MANAGEMENT; HUMANS; RESEARCH; UNITED STATES;

EID: 0041735112     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-003-0109-4     Document Type: Review

References (48)

1. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J Clin 2002, 52:23-47.
2. Nelson H, Petrelli N, Carlin A, et al.: Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001, 93:583-596.
3. Weeks JC, Nelson H, Gelber S, et al.: Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA 2002, 287:321-328.
4. Schrag D, Cramer LD, Bach PB, et al.: Influence of hospital procedure volume on outcomes following surgery for colon cancer. JAMA 2000, 284:3028-3035.
5. Tepper JE, O'Connell MJ, Niedzwiecki D, et al.: Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001, 19:157-163.
6. Stocchi L, Nelson H, Sargent DJ, et al.: Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol 2001, 19:3895-3902.
7. Hodgson DC, Fuchs CS, Ayanian JZ: Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. J Natl Cancer Inst 2001, 93:501-515.
8. Heald RJ, Moran BJ, Ryall RD, et al.: Rectal cancer: the Basing-stoke experience of total mesorectal excision, 1978-1997. Arch Surg 1998, 133:894-899.
9. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al.: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345:638-646.
10. Tepper JE, O'Connell M, Niedzwiecki D, et al.: Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control: final report of Intergroup 0114. J Clin Oncol 2002, 20:1744-1750.
11. Riethmuller G, Holz E, Schlimok G, et al.: Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998, 16:1788-1794.
12. Punt CJ, Nagy A, Douillard JY, et al.: Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002, 360:671-677.
13. Fields AL, Keller AM, Schwartzberg L, et al.: Edrecolomab (171A antibody) (EDR) in combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomized North American phase III study [abstract]. Proc ASCO 2002, 21:508.
14. Mamounas E, Wieand S, Wolmark N, et al.: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999, 17:1349-1355.
15. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT 132) Investigators. J Clin Oncol 1999, 17:1356-1363.
16. Buyse M, Piedbois P: Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 2001, 28(Suppl 1):20-24.
17. Schrag D, Rifas-Shiman S, Saltz L, et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002, 20:3999-4005.
18. NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990, 264:1444-1450.
19. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 2001, 358:1291-1304.
20. Roh M, Petrelli N, Wiend S, et al.: Phase III randomized trial of preoperative versus postoperative multimodality therapy in patients with carcinoma of the rectum (NSABP R-03) [abstract]. Proc ASCO 2001, 20:490.
21. Fong Y: Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin 1999, 49:231-255.
22. Kemeny N, Huang Y, Cohen AM, et al.: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999, 341:2039-2048.
23. Goldberg RM: Adjuvant therapy after resection of liver-limited colorectal cancer metastases. ASCO 2000 Clinical Practice Forum; 2000:73-77.
24. Gryfe R, Kim H, Hsieh ET, et al.: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000, 342:69-77.
25. Jeri J, Kim H, Piantadosi S, et al.: Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med. 1994; 331:213-221.
26. Watanabe T, Wu TT, Catalano PJ, et al.: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001, 344:1196-1206.
27. Salonga D, Danenberg KD, Johnson M, et al.: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000, 6:1322-1327.
28. Iacopetta B, Grieu F, Joseph D, Elsaleh H: A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001, 85:827-830.
29. Allegra C: Thymidylate synthase levels: prognostic, predictive, or both? J Clin Oncol 2002, 20:1711-1713.
30. Elsaleh H, Joseph D, Grieu F, et al.: Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000, 355:1745-1750.
31. Ribic CM, Sargent D, Moore MJ, et al.: Tumor microsatellite instability (MSI) and the benefit of 5-FU based chemotherapy in stage II and III colon cancer: a pooled molecular reanalysis of randomized chemotherapy trials [abstract]. Proc ASCO 2002, 21:509a.
32. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343:905-914.
33. Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-1047.
34. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947.
35. Goldberg RM, Morton RF, Sargent D, et al.: N9741 Oxaliplatin (oxal) or CPT-11 +5-fluorouracil(5FU)/leucovorin(LV) or oxal + CPT11 in advanced colorectal cancer (CRC): initial toxicity and response data from a GI Intergroup study [abstract]. Proc ASCO 2002, 21:511a.
36. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001, 345:144-146.
37. Rothenberg ML, Meropol NJ, Poplin EA, et al.: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001, 19:3801-3807.
38. Douillard JY, Hoff PM, Skillings J, et al.: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002, 20:3605-3616.
39. Carmichael J, Popiela T, Radstone D, et al.: Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002, 20:3617-3627.
40. Van Cutsem E, Sorensen JL, Cassidy J, et al.: International phase III study of oral eniluracil plus 5-fluorouracil versus intravenous 5-FU plus LV in the treatment of advanced colorectal cancer [abstract]. Proc ASCO 2001, 20:523a.
41. Hoff PM, Ansari R, Batist G, et al.: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001, 19:2282-2292.
42. Van Cutsem E, Twelves C, Cassidy J, et al.: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001, 19:4097-4106.
43. Saltz L, Meropol NJ, Loehrer PJ, et al.: Single agent IMC-C225 (Erbitux) has activity in CPT-11 refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR) [abstract]. Proc ASCO 2002, 21:504a.
44. Bergsland E, Hurwitz H, Fehrenbacher L, et al.: A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin to FU/LV alone in patients with metastatic colorectal cancer [abstract]. Proc ASCO 2000, 19:939a.
45. Gianotonio BJ, Levy D, Catalano PJ, et al.: Incorporating angiongenesis inhibition with bevacizumab (anti-VEGF) into frontline chemotherapy with irinotecan (CPT-11), fluorouracil and leucovorin (FU/LV) for advanced colorectal cancer: a toxicity analysis of ECOG study E2200 [abstract]. Proc ASCO 2002, 21:503a.
46. Colorectal Cancer Collaborative Group: Surgery for colorectal cancer in elderly patients: a systematic review. Lancet 2000, 356:968-974.
47. Schrag D, Cramer LD, Bach PB, Begg CB: Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001, 93:850-857.
48. Sargent DJ, Goldberg RM, Jacobson SD, et al.: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001, 345:1091-1097.